Funding for this research was provided by:
Prostate Cancer UK (BO26/MO)
Movember Foundation (BO26/MO)
Received: 17 January 2019
Accepted: 16 September 2019
First Online: 15 October 2019
Ethics approval and consent to participate
: The study received the following approvals: Newcastle & North Tyneside 1 Research Ethics Committee (15/NE/0036), Confidentiality Advisory Group (15/CAG/0110), NHS Scotland Public Benefit and Privacy Panel (0516-0364), Office of Research Ethics Northern Ireland (16/NI/0073) and NHS R&D approval from Wales, Scotland and Northern Ireland. Eligible patients consented to be included by return of a completed questionnaire.
: Not Applicable.
: DD, TK, SW, AD, EW, RW, AWG and AG report funding from Prostate Cancer UK & Movember Foundation during the conduct of the study. AD declares membership of the BMC Cancer editorial board (Associate Editor). MM declares other relationship from Endocyte. WC declares research funding from Myriad Genetics, consultancy or advisory role from Bayer, Speakers Bureau from Prostate Cancer UK. All other authors declare no conflicts of interest.